But what about the other end of the spectrum? Let's take a quick look at the two worst performers on the Nasdaq-100 in May 2025.

New York and 27 other states sued bankrupt genetic testing company 23andMe to block the sale of 15 million customers' ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...

Multiple states and the District Columbia are pushing back on bankrupt 23andMe’s plans to sell customer genetic information ...

A talk with study author on a new combination of acimtamig and an allogeneic natural killer cell product that shows safety ...

The DNA of 15 million people was sold after 23andMe filed for bankruptcy and was acquired by pharmaceutical giant Regeneron.

Lawmakers raised questions and concerns about the sale of genetic-testing company 23andMe during a hearing on Tuesday.

Twenty-seven states, including Illinois and Wisconsin, and the District of Columbia on Monday filed a lawsuit in bankruptcy ...

The bipartisan lawsuit was filed on Monday in St. Louis alongside a separate objection to the bankruptcy sale and is being ...

WilmerHale said it’s representing the law professor tapped to make privacy-related recommendations about the sale of ...